MAP2K7 and non-small cell lung carcinoma: For example, Pasi et al. found that the addition of the MEK inhibitor trametinib to docetaxel did not improve progression-free survival in advanced KRAS-mutant non-small cell lung cancer patients compared to docetaxel alone [37].